Puma Biotechnology Inc (PBYI) Stock Rating Reaffirmed by Leerink Swann

Puma Biotechnology Inc (NYSE:PBYI)‘s stock had its “outperform” rating restated by analysts at Leerink Swann in a report released on Monday. They currently have a $115.00 price objective on the biopharmaceutical company’s stock. Leerink Swann’s price target indicates a potential upside of 32.49% from the stock’s current price.

PBYI has been the subject of a number of other reports. Credit Suisse Group reissued an “outperform” rating and issued a $58.00 price target on shares of Puma Biotechnology in a report on Tuesday, April 18th. Stifel Nicolaus reissued a “buy” rating and issued a $88.00 price target on shares of Puma Biotechnology in a report on Wednesday, April 19th. Royal Bank Of Canada set a $40.00 price target on shares of Puma Biotechnology and gave the company a “hold” rating in a report on Wednesday, May 10th. Zacks Investment Research raised shares of Puma Biotechnology from a “hold” rating to a “buy” rating and set a $36.00 price objective for the company in a research note on Tuesday, May 16th. Finally, Citigroup Inc. reaffirmed a “buy” rating and set a $88.00 price objective on shares of Puma Biotechnology in a research note on Monday, May 22nd. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $89.75.

Puma Biotechnology (PBYI) opened at 86.90 on Monday. The company has a 50 day moving average of $70.29 and a 200-day moving average of $44.73. The stock’s market capitalization is $3.21 billion. Puma Biotechnology has a 52-week low of $28.35 and a 52-week high of $92.00.

Puma Biotechnology (NYSE:PBYI) last posted its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($1.97) earnings per share for the quarter, topping the consensus estimate of ($2.06) by $0.09. Equities research analysts anticipate that Puma Biotechnology will post ($8.50) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This story was first posted by BBNS and is the property of of BBNS. If you are reading this story on another site, it was illegally copied and reposted in violation of United States and international trademark & copyright legislation. The original version of this story can be accessed at https://baseballnewssource.com/markets/puma-biotechnology-inc-pbyi-stock-rating-reaffirmed-by-leerink-swann/1180489.html.

In other Puma Biotechnology news, major shareholder Adage Capital Partners Gp, L.L sold 1,235,700 shares of the stock in a transaction that occurred on Friday, May 26th. The stock was sold at an average price of $75.38, for a total transaction of $93,147,066.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last quarter, insiders have sold 1,990,088 shares of company stock worth $157,553,113. Corporate insiders own 22.70% of the company’s stock.

Large investors have recently bought and sold shares of the stock. FMR LLC boosted its stake in Puma Biotechnology by 2.4% in the first quarter. FMR LLC now owns 3,540,729 shares of the biopharmaceutical company’s stock valued at $131,715,000 after buying an additional 81,410 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Puma Biotechnology by 7.2% in the first quarter. Wellington Management Group LLP now owns 2,539,350 shares of the biopharmaceutical company’s stock valued at $94,464,000 after buying an additional 170,812 shares during the period. Vanguard Group Inc. boosted its position in shares of Puma Biotechnology by 4.4% in the first quarter. Vanguard Group Inc. now owns 2,428,909 shares of the biopharmaceutical company’s stock valued at $90,355,000 after buying an additional 101,722 shares during the period. State Street Corp boosted its position in shares of Puma Biotechnology by 113.1% in the fourth quarter. State Street Corp now owns 1,946,098 shares of the biopharmaceutical company’s stock valued at $59,746,000 after buying an additional 1,032,915 shares during the period. Finally, Redmile Group LLC boosted its position in shares of Puma Biotechnology by 33.7% in the first quarter. Redmile Group LLC now owns 1,725,414 shares of the biopharmaceutical company’s stock valued at $64,185,000 after buying an additional 435,274 shares during the period. 80.98% of the stock is owned by institutional investors.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Analyst Recommendations for Puma Biotechnology (NYSE:PBYI)

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with our FREE daily email newsletter.

 


Latest News

Todd Frazier Traded to Yankees for Blake Rutherford and Others
Todd Frazier Traded to Yankees for Blake Rutherford and Others
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Todd Frazier Trade to Boston Appears to Be Decided
Todd Frazier Trade to Boston Appears to Be Decided
Chicago White Sox Continue Rebuild Without Jose Quintana
Chicago White Sox Continue Rebuild Without Jose Quintana
Mike Trout Returns from Injury With Single and Stole Base
Mike Trout Returns from Injury With Single and Stole Base
Chicago Cubs Strengthen Rotation Through Trade for Jose Quintana
Chicago Cubs Strengthen Rotation Through Trade for Jose Quintana


Leave a Reply

 
© 2006-2017 BBNS.